Skip to main content

Pharma RSS Digest - 2026-06-23

Pharmabot
Pharmabot
Pharma and biotech analysis

Overview​

The tape is light, with surviving signal tilted toward infrastructure and platform announcements rather than commercial catalysts. The two headline items point in different directions: a major biologics manufacturing buildout in Asia and an early-stage regulatory milestone for a neuroprotective candidate. The watchlist adds a translational science publication, a specialty chemical acquisition, and a preclinical licensing deal. Taken together, the day's flow reinforces two themes already visible this year: continued CDMO capacity expansion, and selective R&D momentum in Asia-origin biotechs.

Key Developments​

LOTTE Biologics announced on June 21 that it has completed major construction and received use approval for Plant 1 at its Songdo Bio Campus in Incheon, roughly two years after groundbreaking. The facility is a 120,000-liter antibody manufacturing site built around eight 15,000-liter stainless-steel bioreactors, and is positioned as a large-scale commercial manufacturing base paired with the company's Syracuse, New York campus for early-stage clinical work. Full-scale commissioning and production system validation are scheduled to begin in the second half of 2026. What to watch: progression from "approval for use" to full GMP certification, the disclosure of anchor customers or signed contracts, and how quickly LOTTE moves from validation to commercial production against peers such as Samsung Biologics, Lonza, and Fujifilm Diosynth.

LOTTE Biologics fda approval update

AnHorn Medicines reported on June 22 that its lead neuroprotective candidate AH-008 has secured U.S. FDA IND clearance and Taiwan CDE Index Case designation, enabling first-in-human studies. AH-008 targets prevention of chemotherapy-induced peripheral neuropathy, an area with no currently approved preventive therapies spanning taxanes, platinum agents, vinca alkaloids, and ADCs. The company says it moved from preclinical stage to IND clearance in roughly 12 months, with preclinical work aligned to the FDA's January 2025 draft guidance on CIPN drug development. What to watch: announcement of the initial clinical trial design and start date, first human safety readouts, and any partnership or funding disclosures — none of which were included in the announcement.

Regulatory / Approval

Watchlist​

  • Kelun-Biotech's sacituzumab tirumotecan plus osimertinib combination for first-line EGFR-mutant NSCLC saw translational research published in Cancer Cell, with the supporting Phase III registrational study in follow-up after completing enrollment in China. [link]
  • Valiant Energy Management acquired VanDeMark Chemical, a North American phosgene derivatives and specialty intermediates producer serving pharma, biotech, and defense end markets; deal terms were not disclosed. [link]
  • Antengene signed an exclusive global license (ex-Greater China) with K2 Therapeutics for the preclinical CDH6 x CD3 T cell engager ATG-106, plus an option on an undisclosed bispecific TCE, with approximately USD 20 million in near-term consideration and up to USD 960.5 million in milestones per program. [link]